Core Viewpoint - Q-tech preannounced a significant net profit growth of 150-180% YoY for 1H25, with a mid-point of RMB305 million, surpassing Bloomberg consensus by 20% and tracking 54% of the FY25E net profit estimate [1][2]. Financial Performance - For 1H25, Q-tech's estimated revenue and net profit growth were 7% and 162% YoY, respectively, driven by a 2% YoY increase in CCM (with non-mobile CCM up 97%) and a 100% YoY increase in FPM (with ultrasonic FPM up 20x) [2]. - The gross profit margin (GPM) improved to 7.1% in 1H25, compared to 5.2% in 1H24 and 6.9% in 2H24, attributed to HCM spec upgrades and higher-margin non-mobile CCM and ultrasonic FPM shipments [2]. Outlook - The outlook for 2H25 is positive, with expectations of continued strong momentum driven by high-end smartphone camera upgrades (OIS/periscope), IoT/auto CCM growth, and GPM recovery [2]. - Revenue and net profit are estimated to grow by 25% and 162% YoY in 2H25E, respectively, supported by a 23% mix of high-end HCM in 2H and an 85% revenue increase in IoT/auto [2]. Earnings Estimates - The company raised FY25-27E EPS estimates by 21-30%, reflecting strong 1H25 performance and improved GPM outlook for FY26/27E, with EPS now 14-19% above consensus [1][3]. - The new target price (TP) is set at HK$13.21, based on a higher 19.5x FY25E P/E, aligning with the 10-year historical average forward P/E, following sector re-rating and a stronger outlook for FY26-27E [1][3]. Investment Thesis - Q-tech is positioned to capture high-end smartphone camera upgrade demand and momentum in IoT/auto CCM modules, leading to a reiteration of the BUY rating [3].

21世纪经济报道记者骆轶琪 广州报道 随着国内头部GPU芯片公司相继奔赴上市，国产GPU生态的发展进程更清晰地呈现。 21世纪经济报道记者梳理发现，多家国产GPU芯片公司在2024年迎来收入和未来潜在收益的大爆发，这 得益于近年来国内市场对AI智算需求的跃升。 今年初，DeepSeek兴起进一步引发的浪潮也在推动国内AI芯片需求，尤其是在AI端侧落地方面。因此 在今年前三个月，国内头部GPU芯片公司的收入再度实现快速成长，印证了业绩成长的可持续性。 当然在自主架构、软件生态体系构建方面，国内AI芯片仍在蓄力。这在一定程度上，成为影响公司盈 利能力的条件。 因此在2024年，公司主营业务毛利率高达72.32%，但在2023年这一数字还是27.84%。可见，AI智算带 动了更高的产品价值。 沐曦集成电路面临类似的情况。招股书显示，2024年公司主营业务收入为7.42亿元，同比暴增 1354.9%（2023年主营收入5141.09万元）。 该公司也经历了主要业务的变化，2024年，训推一体系列是公司的核心收入来源，其中GPU板卡方面占 总收入的68.99%，GPU服务器占比28.29%；在2023年，GPU服务器还 ...

2025年6月18日，中国人民银行行长潘功胜在2025陆家嘴论坛上，同与会人员分享了其关于全球金融治理的若干思考。讲话中，潘功胜强调了新兴技术在 跨境支付领域中加速应用的现状："区块链和分布式账本等新兴技术推动央行数字货币、稳定币蓬勃发展，实现了'支付即结算'，从底层重塑传统支付体 系，大幅缩短跨境支付链条，同时对金融监管也提出了巨大的挑战。智能合约、去中心化金融等技术也将持续推动跨境支付体系的演进和发展。" 随着讲话稿的逐步传播，稳定币、区块链、web3.0等技术再一次被推上了舆论高潮。毫无疑问，随着全球数字化转型浪潮的深入推进，区块链技术正在重 塑各行业的信任机制与数据交互模式。而在中国，区块链产业从探索期迈向深化应用期，数据要素借由区块链技术达成了自身价值释放，相关企业从技术 追随者开始跃升成为标准制定者。 在2025年7月2日发布的"2025年《财富》中国最具影响力的商界女性"未来榜中，来自趣链科技的首席执行官、正高级工程师邱炜伟女士赫然在列。而她领 导的趣链科技作为区块链领域的领军者，凭借"国产、自主、可控"的技术路线，已经实现从基础研发到全栈产品落地的跨越，服务超过300家国家机构及 头部企业，支 ...

ADHD is a chronic neurobiological and developmental disorder that affects millions of children and often continues into adulthood. The condition is marked by an ongoing pattern of inattention and/or hyperactivity- impulsivity that interferes with functioning or development. In the U.S., over 20 million patients have been diagnosed with ADHD. Among this group, 12 million are adults and over 8 million are under the age of 17. According to the CDC, just 53.6 percent of all children and teens with ADHD reported ...

[Music] Hello and welcome to the inaugural episode of Hot Girl Vergecast Summer, the flagship podcast where the hot girls of the Verge replace uh our stinky old men for a summer. No, we love you. We love you. You're not stinky and you're not old. But uh anyway, I'm your friend Victoria Song and I'm filling in this week for David Pierce. Now that he's officially on parental leave. I'll be your guest host for the next two weeks and then I will be handing it off to another one of my beautiful colleagues. It's ...

新能源及有色金属日报 | 2025-07-08 政策及资金扰动持续，多晶硅盘面继续反弹 工业硅： 市场分析 2025-07-07，工业硅期货价格偏弱震荡，主力合约2509开于7980元/吨，最后收于8045元/吨，较前一日结算变化（55） 元/吨，变化（0.69）%。截止收盘，2509主力合约持仓384707手，2025-07-08仓单总数为51349手，较前一日变化 -352手。 供应端：工业硅现货价格持稳。据SMM数据，昨日华东通氧553#硅在8700-8800（0）元/吨；421#硅在8900-9200 （0）元/吨，新疆通氧553价格8000-8200（0）元/吨，99硅价格在8000-8100（0）元/吨。昆明、四川地区部分硅价 仍下降。黄埔港、天津、西北、上海、新疆地区硅价暂稳。 97硅价格同样暂稳。 消费端：据SMM统计，有机硅DMC报价10300-10600（0）元/吨。据SMM统计，6月国内有机硅DMC产量环比5月 增加13.75％，同比减少1.60％。6月国内多数有机硅单体企业开工负荷有所提高。7月虽国内仍有部分单体企业开 工负荷有所下降，但整体影响量较为有限，7月预估有机硅产量环比6月上 ...

Group 1 - iShares MSCI South Korea ETF listed in the US declined by 3.56%, closing at $70.11 [1] - iShares MSCI Japan ETF listed in the US fell by 2.39%, ending at $72.815 [1] - iShares MSCI South Africa ETF listed in the US decreased by 1.73%, closing at $53.84, while the South African Rand maintained a decline of over 1.55%, currently at 17.8504 Rand per US dollar [1] Group 2 - VanEck Vietnam ETF listed in the US increased by 1.78%, closing at $14.208 [1] - Global X MSCI Vietnam ETF listed in the US rose by 1.10% [1]

Core Insights - Tempus AI (TEM) is advancing precision medicine through a strong pipeline of R&D initiatives, including the introduction of xM, a liquid biopsy assay for advanced solid tumors, and the launch of the Fuses program to enhance AI-enabled diagnostics [1][2][3] Product Development - The company launched olivia, an AI-enabled personal health concierge app, and an FDA-approved NGS-based in vitro diagnostic device, xT CDx, for solid tumor profiling [2] - Tempus AI is developing its first whole-genome sequencing test, xH, aimed at supporting personalized therapy in hematological oncology [3] Competitive Landscape - Peers like Veracyte (VCYT) and Myriad Genetics (MYGN) are also innovating in precision diagnostics, with Veracyte launching the Decipher Prostate test and Myriad introducing the Prequel Prenatal Screen and Foresight Carrier Screening test [4][5] Financial Performance - Over the past year, Tempus AI shares have increased by 83.6%, outperforming the industry growth of 38% and the S&P 500's 12.3% [6] - The company's current forward Price-to-Sales (P/S) ratio is 7.50X, higher than the industry average of 5.88X [8] Earnings Estimates - Earnings estimates for Tempus AI show a mixed outlook for 2025 and 2026, with current estimates remaining stable over the past month [10][11]

Entera Bio's N-Tab Platform and Pipeline - Entera Bio's proprietary N-Tab platform transforms peptides into orally bioavailable tablets, potentially unlocking patient acceptance and driving superior health outcomes[7, 19] - The company's lead asset, EB613, is a differentiated Phase 3 asset poised for blockbuster sales as a first-in-class oral PTH(1-34) anabolic tablet treatment for osteoporosis, a condition affecting over 200 million people worldwide[7, 27] - Entera has a rich pipeline with multiple blockbuster opportunities in high-impact therapeutic areas, including EB612 for hypoparathyroidism, OXM for obesity/metabolic disorders, and GLP-2 for GI inflammatory disorders and short bowel syndrome[7, 8] - The company's cash runway extends into H2 2026, with multiple catalysts expected in the next 12 months[8] EB613 for Osteoporosis - EB613 is positioned as the first oral anabolic treatment to support earlier intervention in osteoporosis, addressing a substantial treatment gap[7, 28] - A Phase 2 study of EB613 in post-menopausal women with low bone mass or osteoporosis demonstrated a faster onset of action and higher increases in BMD at the cortical bone (femoral neck and hip region)[23] - EB613's Phase 2 results showed a distinct dual mechanism of increased bone formation (P1NP) and reduced bone resorption (CTX)[44] - Phase 2 data indicated that EB613 increased BMD at all major skeletal sites, with placebo-adjusted BMD change of EB613 2.5mg from Baseline to Month 6 as Compared with Published Forteo® Data[56, 57] GLP-1/Glucagon and GLP-2 Programs - Entera is developing an oral GLP-1/Glucagon (OXM) dual agonist tablet for metabolic disorders and obesity in partnership with OPKO, with an IND filing expected late 2025/early 2026[8, 104, 116] - Pre-clinical data supports the development of once-daily oral GLP-2 analog tablets for short bowel syndrome (SBS), a rare disease affecting approximately 30,000 patients across the US and EU[8, 106, 108]

Core Insights - Tempus AI is experiencing strong operational momentum with significant revenue and gross profit growth, transitioning from a high-growth startup to a scalable enterprise AI and diagnostics company [1][2] Revenue and Profit Growth - In Q4 2024, Tempus AI reported a 35.8% year-over-year revenue growth and a 49.7% increase in gross profit, primarily driven by its high-margin Data and Services segment [2] - For Q1 2025, revenues grew by 34% and gross profit increased by 45%, with gross margin rising from 42.5% to 44.5% [2][7] - The improvements were attributed to lab efficiencies, increased adoption of AI tools like Tempus One and xM, and a higher mix of data services [2][7] Future Earnings Expectations - The upcoming Q2 2025 earnings release is anticipated to show further margin expansion and sequential gains in adjusted EBITDA, supported by new offerings such as Tempus One in EHR systems and the xM liquid biopsy assay [3] - Any upward revision to guidance or increase in contract value, especially from large enterprise deals, could enhance the momentum observed in early 2025 [3] Competitive Landscape - Tempus AI's peers, such as Guardant Health and Natera, are also making significant advancements in AI-driven diagnostics, with Guardant Health introducing new assays and Natera expanding its market reach [6][8] - Natera reported a 36.5% revenue growth in Q1 2025, with gross margin expansion to 63.1%, indicating a competitive environment in personalized oncology [8] Earnings Estimates - The Zacks Consensus Estimate for Tempus AI's 2025 earnings suggests a 56.3% year-over-year improvement [9] - Current estimates indicate a potential for significant growth in earnings per share, with a year-over-year growth estimate of 63.49% for the current quarter [10] Valuation Metrics - Tempus AI currently trades at a forward Price-to-Sales (P/S) ratio of 7.52X, which is higher than the industry average of 5.8X, indicating a potentially expensive valuation [11]